IOL Chemicals and Pharmaceuticals Limited (IOLCP.BO)
INR 61.73
(4.08%)
INR 61.73
(4.08%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 21.18 Billion INR | -3.13% |
| 2022 | 22.01 Billion INR | 1.54% |
| 2021 | 21.68 Billion INR | 11.42% |
| 2020 | 19.46 Billion INR | 4.43% |
| 2019 | 18.63 Billion INR | 12.6% |
| 2018 | 16.55 Billion INR | 72.01% |
| 2017 | 9.62 Billion INR | 37.09% |
| 2016 | 7.01 Billion INR | 20.92% |
| 2015 | 5.8 Billion INR | 50.86% |
| 2014 | 3.84 Billion INR | -31.73% |
| 2013 | 5.63 Billion INR | 17.03% |
| 2012 | 4.81 Billion INR | 2.3% |
| 2011 | 4.7 Billion INR | 20.87% |
| 2010 | 3.89 Billion INR | 11.44% |
| 2009 | 3.49 Billion INR | 15.76% |
| 2008 | 3.01 Billion INR | -5.06% |
| 2007 | 3.17 Billion INR | 56.94% |
| 2006 | 2.02 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 5.02 Billion INR | -0.31% |
| 2023 FY | 21.32 Billion INR | -3.13% |
| 2023 Q4 | 5.03 Billion INR | -3.16% |
| 2023 Q3 | 5.2 Billion INR | -4.57% |
| 2023 Q2 | 5.45 Billion INR | -3.17% |
| 2023 Q1 | 5.63 Billion INR | -1.51% |
| 2022 Q4 | 5.71 Billion INR | 9.23% |
| 2022 Q2 | 5.41 Billion INR | -4.18% |
| 2022 Q1 | 5.65 Billion INR | 1.47% |
| 2022 FY | 22.01 Billion INR | 1.54% |
| 2022 Q3 | 5.23 Billion INR | -3.31% |
| 2021 Q1 | 5.18 Billion INR | 17.97% |
| 2021 Q3 | 5.55 Billion INR | 3.21% |
| 2021 FY | 21.68 Billion INR | 11.42% |
| 2021 Q2 | 5.37 Billion INR | 3.74% |
| 2021 Q4 | 5.56 Billion INR | 0.31% |
| 2020 Q1 | 4.6 Billion INR | 12.09% |
| 2020 Q4 | 4.39 Billion INR | -14.32% |
| 2020 Q2 | 5.33 Billion INR | 15.95% |
| 2020 FY | 19.46 Billion INR | 4.43% |
| 2020 Q3 | 5.13 Billion INR | -3.84% |
| 2019 Q3 | 5.11 Billion INR | 13.87% |
| 2019 Q1 | 4.92 Billion INR | 25.72% |
| 2019 FY | 18.63 Billion INR | 12.6% |
| 2019 Q4 | 4.1 Billion INR | -19.71% |
| 2019 Q2 | 4.48 Billion INR | -8.9% |
| 2018 Q3 | 4.78 Billion INR | 13.09% |
| 2018 Q2 | 4.22 Billion INR | 16.88% |
| 2018 Q1 | 3.61 Billion INR | 25.85% |
| 2018 FY | 16.55 Billion INR | 72.01% |
| 2018 Q4 | 3.91 Billion INR | -18.05% |
| 2017 Q3 | 2.62 Billion INR | 20.61% |
| 2017 FY | 9.62 Billion INR | 37.09% |
| 2017 Q4 | 2.87 Billion INR | 9.46% |
| 2017 Q1 | 2.15 Billion INR | 11.39% |
| 2017 Q2 | 2.17 Billion INR | 1.15% |
| 2016 FY | 7.01 Billion INR | 20.92% |
| 2016 Q4 | 1.93 Billion INR | 5.61% |
| 2016 Q3 | 1.83 Billion INR | 6.2% |
| 2016 Q2 | 1.72 Billion INR | 6.4% |
| 2016 Q1 | 1.61 Billion INR | 13.92% |
| 2015 Q2 | 1.58 Billion INR | 15.48% |
| 2015 Q4 | 1.42 Billion INR | -0.68% |
| 2015 FY | 5.8 Billion INR | 50.86% |
| 2015 Q1 | 1.36 Billion INR | 83.01% |
| 2015 Q3 | 1.43 Billion INR | -9.48% |
| 2014 FY | 3.84 Billion INR | -31.73% |
| 2014 Q4 | 748.27 Million INR | 10.37% |
| 2014 Q3 | 677.94 Million INR | -44.08% |
| 2014 Q2 | 1.21 Billion INR | 0.31% |
| 2014 Q1 | 1.2 Billion INR | -6.81% |
| 2013 Q4 | 1.29 Billion INR | -6.54% |
| 2013 FY | 5.63 Billion INR | 17.03% |
| 2013 Q1 | 1.39 Billion INR | 2.69% |
| 2013 Q2 | 1.54 Billion INR | 11.35% |
| 2013 Q3 | 1.38 Billion INR | -10.43% |
| 2012 Q2 | 1.04 Billion INR | -16.48% |
| 2012 Q3 | 1.17 Billion INR | 12.74% |
| 2012 Q4 | 1.35 Billion INR | 15.34% |
| 2012 FY | 4.81 Billion INR | 2.3% |
| 2012 Q1 | 1.24 Billion INR | 0.0% |
| 2011 FY | 4.7 Billion INR | 20.87% |
| 2010 FY | 3.89 Billion INR | 11.44% |
| 2009 FY | 3.49 Billion INR | 15.76% |
| 2008 FY | 3.01 Billion INR | -5.06% |
| 2007 FY | 3.17 Billion INR | 56.94% |
| 2006 FY | 2.02 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 95.631% |
| NATCO Pharma Limited | 40.02 Billion INR | 47.052% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -101.546% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -717.361% |
| Achyut Healthcare Limited | 61.36 Million INR | -34428.182% |
| Ajanta Pharma Limited | 42.08 Billion INR | 49.653% |
| Alkem Laboratories Limited | 126.67 Billion INR | 83.273% |
| Alpa Laboratories Limited | 1.08 Billion INR | -1848.666% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 65.332% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -63.559% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 92.618% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -347.588% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -175.102% |
| Brooks Laboratories Limited | 794.86 Million INR | -2565.825% |
| Divi's Laboratories Limited | 78.45 Billion INR | 72.99% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 92.41% |
| Eris Lifesciences Limited | 20.09 Billion INR | -5.466% |
| FDC Limited | 19.42 Billion INR | -9.059% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 82.063% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 7.194% |
| Granules India Limited | 45.06 Billion INR | 52.979% |
| Gufic Biosciences Limited | 8.06 Billion INR | -162.681% |
| Hester Biosciences Limited | 3.04 Billion INR | -595.777% |
| Indoco Remedies Limited | 17.89 Billion INR | -18.414% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -65.427% |
| Ipca Laboratories Limited | 76.22 Billion INR | 72.201% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -915.304% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -4102.493% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1930.92% |
| Laurus Labs Limited | 50.01 Billion INR | 57.636% |
| Lupin Limited | 200.1 Billion INR | 89.411% |
| Mankind Pharma Limited | 103.34 Billion INR | 79.497% |
| Medicamen Biotech Limited | 1.79 Billion INR | -1081.755% |
| Medico Remedies Limited | 1.44 Billion INR | -1362.151% |
| Megasoft Limited | 373.95 Million INR | -5566.381% |
| Piramal Pharma Limited | 81.71 Billion INR | 74.068% |
| RPG Life Sciences Limited | 5.82 Billion INR | -264.051% |
| Sigachi Industries Limited | 3.98 Billion INR | -431.126% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -2704.887% |
| Unichem Laboratories Limited | 16.57 Billion INR | -27.847% |
| Wanbury Limited | 5.75 Billion INR | -268.099% |
| Windlas Biotech Limited | 6.3 Billion INR | -235.833% |
| ZIM Laboratories Limited | 3.67 Billion INR | -476.706% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 88.86% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -84.056% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -403.04% |
| Bal Pharma Limited | 3.39 Billion INR | -524.657% |
| Strides Pharma Science Limited | 40.51 Billion INR | 47.695% |
| Venus Remedies Limited | 5.91 Billion INR | -258.266% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | -16.715% |
| Nectar Lifesciences Limited | 16.84 Billion INR | -25.823% |
| Shilpa Medicare Limited | 11.51 Billion INR | -84.001% |
| Aarti Drugs Limited | 25.28 Billion INR | 16.199% |
| Suven Life Sciences Limited | 116.92 Million INR | -18021.766% |
| Ind-Swift Limited | 5.02 Billion INR | -321.71% |
| Valiant Laboratories Limited | 1.82 Billion INR | -1063.898% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 39.183% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -71.106% |
| Themis Medicare Limited | 3.81 Billion INR | -455.049% |
| Hikal Limited | 17.84 Billion INR | -18.736% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 80.02% |
| Sequent Scientific Limited | 13.69 Billion INR | -54.699% |
| Novartis India Limited | 3.35 Billion INR | -532.393% |
| Wockhardt Limited | 27.89 Billion INR | 24.024% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 68.387% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -5192.729% |
| Neuland Laboratories Limited | 15.58 Billion INR | -35.954% |
| Morepen Laboratories Limited | 17.01 Billion INR | -24.506% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -1272.628% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -474.875% |